Properties (47)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Gavis_Pharmaceuticals_(2015)
Merck_KGaA's_generics_business_(2014) RPG_Life_Sciences_(2007) |
| gptkbp:awards |
Best Company in the Pharmaceutical Sector (2020)
Best Employer Brand Award (2019) Pharma_Company_of_the_Year_(2018) |
| gptkbp:CEO |
gptkb:Vinita_Gupta
|
| gptkbp:clinicalTrials |
Conducts clinical trials globally
|
| gptkbp:employees |
over 20,000
|
| gptkbp:founded |
1968
|
| gptkbp:founder |
gptkb:Desh_Bandhu_Gupta
|
| gptkbp:globalPresence |
Over 100 countries
|
| gptkbp:headCoach |
20,000+
|
| gptkbp:headquarters |
gptkb:Mumbai,_India
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lupin Limited
|
| gptkbp:market |
gptkb:Asia
gptkb:North_America Europe $10 billion (2021) |
| gptkbp:partnerships |
gptkb:AstraZeneca
gptkb:Mylan gptkb:Bristol-Myers_Squibb Novartis Sanofi |
| gptkbp:patentCitation |
Over 1,000 patents filed
|
| gptkbp:productionCompany |
15 manufacturing sites
|
| gptkbp:products |
Branded drugs
Active pharmaceutical ingredients (APIs) Generic_drugs |
| gptkbp:R&D |
6 R&D centers
|
| gptkbp:researchAndDevelopment |
Focus on chronic diseases
Focus on cardiovascular diseases Focus on anti-infectives Focus on diabetes Focus on central nervous system disorders |
| gptkbp:revenue |
$2.1 billion (2021)
|
| gptkbp:socialResponsibility |
Education initiatives
Environmental sustainability programs Healthcare_initiatives |
| gptkbp:stockExchange |
gptkb:BSE
NSE |
| gptkbp:stockSymbol |
LUPIN
|
| gptkbp:subsidiary |
gptkb:Lupin_Pharmaceuticals,_Inc.
gptkb:Lupin_Life_Sciences Lupin Healthcare |
| gptkbp:website |
www.lupin.com
|